Articles tagged with: Revlimid

NewsFlash »

[ by | Sep 9, 2013 3:17 pm | 4 Comments ]

Reovirus Strain Shows Promise As An Anti-Myeloma Agent In Preclinical Study – Canadian researchers recently found that a specific strain of the reovirus may be an effective therapy for depleting residual multiple myeloma cells from stem cells collected for stem cell trans­planta­tion. Specifically, the researchers found that the virus was able to kill multiple myeloma cells in human stem cell samples without affecting the healthy blood stem cells.  The researchers took human stem cell samples, added multiple myeloma cells to get a tumor burden of 2 percent to 6 percent, incubated the samples with either live or dead reovirus, and trans­planted the stem cells into immuno­com­pro­mised mice.  All of the mice trans­planted with stem cells incubated with the dead virus developed myeloma, while none of the mice trans­planted with stem cells incubated with the live virus showed any signs of multiple myeloma. Reoviruses are typically found in the lungs and gastrointestinal tracts of animals.  Many are not associated with any known illness.  Previous studies have found that reovirus strains can selectively target and destroy cancer cells, while simultaneously triggering an immune response that helps destroy additional cancer cells. The reovirus strain tested in the Canadian study, reovirus serotype 3 (strain Dearing), also goes by the brand name Reolysin.  It is under development by the company Oncolytics Biotech, and is currently being studied in a Phase 1 clinical trial as a monotherapy for relapsed or refractory multiple myeloma.  For more in­for­ma­tion, please refer to the study in the journal Bone Marrow trans­plantation (abstract).

CD44 May Be A Good Indicator Of Revlimid Resistance In Myeloma – Findings from a recent preclinical study conducted at M. D. Anderson indicate that the protein CD44 may be a good marker of Revlimid (lena­lidomide) resistance in multiple myeloma. In particular, the researchers found that Revlimid-resistant myeloma cells had significantly higher levels of CD44 compared to Revlimid-sensitive myeloma cells. CD44 is a protein that is involved in keeping cells attached to tissue; myeloma cells high in CD44 bind to bone marrow tissue, thereby resisting treatment with Revlimid. Another marker for Revlimid-resistance that has been recently discovered is cereblon; myeloma cells with low levels of cereblon do not respond to treatment with Revlimid (see related Beacon news). The M.D. Anderson researchers also found that the leukemia drug tretinoin (all-trans retinoic acid, Vesanoid) was able to reduce the amount of CD44 in myeloma cells and re-sensitized myeloma cells to Revlimid therapy in both human and mice samples. Based on the findings, the investigators believe that a combination of tretinoin and Revlimid may be effective in Revlimid-resistant patients. For more information, please refer to the study in the journal Leukemia (abstract).

Snake Venom Shows Anti-Myeloma Activity – Results from a recent preclinical study conducted in the Middle East show that venom from the desert black snake, also known as the desert cobra or desert python, may have anti-myeloma activity. The snake venom was administered by itself or inside of nanoparticles, which are extremely small objects that can deliver drugs to specific cells in the body. The researchers found that, in mice with multiple myeloma, the anti-myeloma effect of the snake venom was greater when delivered inside of nanoparticles. Previous preclinical studies have shown that snake venom also may be effective in treating solid tumors, such as breast, colon, and prostate cancer. For more information, please refer to the study in the journal Cellular Immunology (abstract).


[ by | Sep 6, 2013 5:48 pm | 13 Comments ]
Study Finds Revlimid-Dexamethasone Is Effective And Safe For Relapsed/Refractory Myeloma In ‘The Real World’

A recent Greek study looks at the efficacy and safety of Revlimid plus dexa­metha­sone for relapsed and refractory multiple myeloma patients in ‘the real world’ — that is, in patients being treated in standard clinical practice rather than clinical trials.

The study’s findings confirm that Revlimid (lenalidomide) plus dexa­metha­sone (Decadron) is effective and safe in day-to-day use among relapsed myeloma patients.

The majority of the patients in the study (77 percent) responded to treat­ment with Revlimid and dexa­metha­sone, with 20 percent achieving a complete response. According to the …

Read the full story »


[ by and | Sep 4, 2013 9:21 pm | 2 Comments ]
Kyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?

A new retrospective study provides insight into the benefit the new mye­lo­ma drugs Kyprolis and Pomalyst may provide to patients who are re­sis­tant to, or cannot tolerate, both Velcade and Revlimid.

The study’s results highlight how challenging it can be to find an effective treat­ment for patients who are “dual refractory” (resistant to both Velcade and Rev­li­mid).

Patients in the study who received either Kyprolis (carfilzomib) or Poma­lyst (poma­lido­mide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …

Read the full story »


[ by | Aug 2, 2013 4:46 pm | 2 Comments ]
Revlimid Plus Dexamethasone Delays Progression And Extends Survival In High-Risk Smoldering Myeloma

Results from a Spanish Phase 3 study published late Wednesday in the New England Journal of Medicine indicate that treatment of high-risk smol­dering multiple myeloma with Revlimid plus dexamethasone delays pro­gression to symptomatic multiple myeloma and extends overall sur­viv­al.

In addition, the Revlimid (lenalidomide)-dexamethasone (Decadron) regi­men had an acceptable safety profile, according to the investigators.

Despite these findings – which would tend to support active treatment of high-risk smoldering myeloma – myeloma experts believe it is too early to begin treating all high-risk smoldering myeloma patients with anti-myeloma therapies. …

Read the full story »


[ by | Jul 19, 2013 4:52 pm | Comments Off ]
Revlimid Leukemia Trial Halted – No Immediate Impact On Drug’s Use In Myeloma Expected

The U.S. pharmaceutical company Celgene (NASDAQ: CELG) reported yester­day the dis­continuation of the com­pany’s Phase 3 study of Revlimid for chronic lympho­cytic leu­kemia.

Preliminary results from the study, which compared treatment with Rev­li­mid (lenalidomide) to treatment with chlorambucil (Leukeran), showed more deaths among patients be­ing treated with Revlimid than those be­ing treated with chlor­ambucil.

The study, known as the “ORIGIN” trial, included 421 previously untreated chronic lymphocytic leukemia (CLL) pa­tients at least 65 years of age.

The U.S. Food and Drug Administration (FDA) also determined that the trial results …

Read the full story »